ARTICLE | Company News

AZ, Lilly to co-develop selective amyloid mAb

December 10, 2016 1:07 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Eli Lilly and Co. (NYSE:LLY) said they partnered to co-develop MEDI1814, a mAb against beta amyloid 42 which is in Phase I testing. Lilly will pay AstraZeneca $30 million up front.

The companies said the collaboration will build on their 2014 deal to co-develop AZD3293 (LY3314814), a beta-site APP-cleaving enzyme (BACE) inhibitor which is in Phase III for mild Alzheimer’s dementia (see BioCentury Extra, Sept. 16, 2014). ...